

PATENT

**CERTIFICATE OF MAILING**

I hereby certify that on 9/24/03, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop DD, P.O. Box 1450, Alexandria, VA 22313-1450.

Trudi Thompson  
Trudi Thompson

Applicant: Fick et al.  
Serial No.: 10/648046  
Filed: 8/25/2003  
Title: SYNTHESIS & METHODS  
OF USE OF PYRIMIDINE  
ANALOGUES &  
DERIVATIVES  
Group Art Unit: Unassigned  
Examiner: Unassigned  
Docket No.: 14377.110

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

Commissioner for Patents  
Mail Stop DD  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. § 1.56, Applicant(s) submit herewith patents, publications, or other information of which they are aware that may be considered in connection with the above-referenced patent application. Submission of this Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein is "material" to Applicants' invention as that term is currently defined in 37 C.F.R. § 1.56 (37 CFR § 1.97(h)).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other relevant information exists.


The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

A Patent and Trademark Office Form 1449 listing each of these informational items is enclosed along with a copy of each item. Copies of the references are not included. They can be found in the parent case, serial number 09/907273.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action issued on the merits of the subject application in accordance with 37 C.F.R. §1.97(b)(3). In the event that a first Office Action has been mailed to the undersigned prior to the mailing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge payment of the applicable fee pursuant to 37 C.F.R. § 1.17(p) to Deposit Account No. 50-1901. A duplicate copy of this document is enclosed.


September 24, 2003

Respectfully submitted,

  
\_\_\_\_\_  
Louis C. Cullman  
Registration No. 39,645

**STRADLING Yocca CARLSON & RAUTH**  
660 Newport Center Drive, Suite 1600  
Newport Beach, CA 92660  
Telephone: 949.725.4000  
Facsimile: 949.725.4100

FORM PTO-1449 (Modified)	ATTY DOCKET NO. 370143-79	SERIAL NO. 09/907,273
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT  David B. Fick et al.	
(Use additional sheets if necessary) PAGE 1 OF 6	FILING DATE July 17, 2001	GROUP 1624



Reference Designation		U.S. PATENT DOCUMENTS					
Examiner Initials		Docket Number	Date	Name	Class	Sub- Class	Filing Date If Appro- priate
	1	3,321,369	05/23/67	Glasky et al.			
	2	3,300,380	01/24/67	Gray et al.			
	3	3,438,968	04/15/69	Glasky et al.			
	4	3,666,856	05/30/72	Elion et al.			
	5	4,035,486	07/12/77	Laborit			
	6	4,138,562	02/06/79	Vince			
	7	4,221,794	09/09/80	Simon et al.			
	8	4,221,909	09/09/80	Simon et al.			
	9	4,221,910	09/09/80	Giner-Sorolla			
	10	4,315,920	02/16/82	Schaeffer et al.			
	11	4,340,726	07/20/82	Simon et al.			
	12	4,347,360	08/31/82	Ogilvie			
	13	4,451,478	05/29/84	Simon et al.			
	14	4,643,992	02/17/87	Goodman et al.			
	15	4,952,693	08/28/90	Sircar et al.			
	16	5,023,244	06/11/91	Goto et al.			
	17	5,091,432	02/25/92	Glasky			
	18	5,093,318	03/03/92	Goodman et al.			
	19	5,187,162	02/16/93	Marangos et al.			
	20	5,237,051	08/17/93	Garbers et al.			
	21	5,256,677	10/26/93	Sham et al.			
	22	5,376,642	12/27/94	Yarchoan et al.			
	23	5,447,939	09/05/95	Glasky			
	24	5,565,437	10/15/96	Marquez et al.			
	25	5,595,901	01/21/97	Rocancourt et al.			
	26	5,795,756	08/18/98	Johnson et al.			
	27	5,801,159	09/01/98	Miller et al.			
	28	5,801,184	09/01/98	Glasky et al.			
	29	5,948,771	09/07/99	Danziger			
	30	6,027,936	02/22/00	Glasky			

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (Modified)	ATTY DOCKET NO. 370143-79	SERIAL NO. 09/907,273
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT David B. Fick et al.	
(Use additional sheets if necessary) PAGE 2 OF 6	FILING DATE July 17, 2001	GROUP 1624

#### FOREIGN PATENT DOCUMENTS

		Docket Number	Date	Country	Class	Sub-Class	Trans-lation	
							Yes	No
	31	WP 99/56550	11.11.99	PCT			X	
	32	WO 99/57119	11.11.99	PCT			X	
	33	WO 99/57120	11.11.99	PCT			X	
							X	

#### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

34	N.W. Tietz, ed., "Textbook of Clinical Chemistry" (W.B. Saunders Co., Philadelphia, 1986), pp. 882-886.
35	G.A. Lyles & B.A. Callingham, "The Effects of Thyroid Hormones on Monoamine Oxidase in the Rat Heart," <u>J. Pharm. Pharmacol.</u> 26: 921-930 (1974).
36	S.K. Gupta & R.K. Mishra, "Desensitization of D <sub>1</sub> Dopamine Receptors Down-Regulates the G <sub>sα</sub> Subunit of G Protein in SK-N-MC Neuroblastoma Cells," <u>J. Mol. Neurosci.</u> 4: 117-123 (1993).
37	S.K. Gupta & R.K. Mishra, "Up-Regulation of D <sub>1</sub> Dopamine Receptors in SK-N-MC Cells After Chronic Treatment with SCH 23390," <u>Neurosci. Res. Commun.</u> 15: 157-166 (1994).
38	P.W. Baures et al., "Design, Synthesis, X-Ray Analysis, and Dopamine Receptor-Modulating Activity of Mimics of the 'C5' Hydrogen-Bonded Conformation in the Peptidomimetic 2-Oxo-3-(R)-[(2(S)-Pyrrolidinylcarbonyl)amino]-1-Pyrrolidineacetamide," <u>J. Med. Chem.</u> 37: 3677-3683 (1994).
39	J.E. Savelli et al., "Modulation of N-Methyl-D-Aspartate (NMDA) Antagonist-Induced Darting Behaviour by the Peptidomimetic PAMTA," <u>Brain Res.</u> 682: 41-49 (1995).
40	K.A. Jacobson, "Chemical Approaches to the Definition of Adenosine Receptors" in <u>Adenosine Receptors</u> (D.M.F. Cooper & C. Londos, eds., <u>Receptor Biochemistry and Methodology</u> , J.C. Venter, L.C. Harrison, eds., Alan R. Liss: New York, 1988), pp. 11:1-26.
41	S.H. Appel & J.L. McManaman, "Is a Breakdown of the Blood-Brain Barrier Cause or Effect?," <u>Neurobiol. Aging</u> 7:512-514 (1986).
42	S.M. MacDonald et al., "Immunological Parameters in the Aged and in Alzheimer's Disease," <u>Clin. Exp. Immunol.</u> 49:123-128 (1982).
43	A.E. Miller et al., "Immunological Studies in Senile Dementia of the Alzheimer Type: Evidence for Enhanced Suppressor Cell Activity," <u>Ann. Neurol.</u> 10:506-510 (1981).
44	K. Stefansson, "Neuroimmunology of Aging" in <u>Clinical Neurology of Aging</u> (M.L. Albert, ed., Oxford University Press, Oxford, (1984)), ch. 4, pp. 76-94.
45	L.R. Weitkamp et al., "Alzheimer Disease: Evidence for Susceptibility Loci on Chromosomes 6 and 14," <u>Am. J. Hum. Genet.</u> 35:443-53 (1983).
46	A. Yamazaki et al., "Synthesis of Guanosine and Its Derivatives from 5-Amino-1-β-D-Ribofuranosyl-4-Imidazolecarboxamide I. Ring Closure with Benzoyl Isothiocyanate," <u>J. Org. Chem.</u> 32:1825-1828 (1967).
47	B. Alhede et al., "A Simple and Efficient Synthesis of 9-Substituted Guanines. Cyclodesulfurization of 1-Substituted 5-[(Thiocarbamoyl)amino]imidazole-4-carboxamides under Aqueous Basic Conditions," <u>J. Org. Chem.</u> 56:2139-2143 (1991).

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (Modified)	ATTY DOCKET NO. 370143-79	SERIAL NO. 09/907,273
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT  David B. Fick et al.	
(Use additional sheets if necessary) PAGE 3 OF 6	FILING DATE July 17, 2001	GROUP 1624

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

48	R.E. Callard & A.J.H. Gearing, "The Cytokine Facts Book" (Academic Press, London, 1994), pp. 99-100, 104-105, 191-200, 235-237.
49	P.J. Middlemiss et al., "AIT-082, a Unique Purine Derivative, Enhances Nerve Growth Factor Mediated Neurite Outgrowth from PC12 Cells," <u>Neurosci. Lett.</u> 199: 131-134 (1995).
50	K.L. Audus et al., "Brain Uptake of Drugs: the Influence of Chemical and Biological Factors," <u>Adv. Drug Res.</u> 23: 1-64 (1992).
51	W.A. Banks & A.J. Kastin, "Measurement of Transport of Cytokines Across the Blood-Brain Barrier," <u>Meth. Neurosci.</u> 16: 67-77 (1993).
52	A.L. Betz, "Identification of Hypoxanthine Transport and Xanthine Oxidase Activity in Brain Capillaries," <u>J. Neurochem.</u> 44: 574-579 (1985).
53	F.G. Blasberg et al., "Transport of $\alpha$ -Aminoisobutyric Acid Across Brain Capillary and Cellular Membranes," <u>J. Cereb. Blood Flow Metab.</u> 3: 8-32 (1983).
54	E.M. Cornford & W.H. Olendorf, "Independent Blood-Brain Barrier Transport Systems for Nucleic Acid Precursors," <u>Biochim. Biophys. Acta</u> 394: 211-219 (1975).
55	A.J. Glasky et al., "Effect of AIT-082, a Purine Analog, on Working Memory in Normal and Aged Mice," <u>Pharmacol. Biochem. Behav.</u> 47: 325-329 (1994).
56	A.J. Glasky et al., "Neurotrophins, Growth Factors and Mimetic Agents as Neuroprotectors in the Treatment of Alzheimer's Disease" in <u>Alzheimer Disease: From Molecular Biology to Therapy</u> (R. Becker & E. Giacobini, eds., Birkhäuser, Boston, 1996), pp. 119-124.
57	E.G. Gutierrez et al., "Murine Tumor Necrosis Factor Alpha Is Transported from Blood to Brain in the Mouse," <u>J. Neuroimmunol.</u> 47: 169-176 (1993).
58	M. Hosokawa & M. Ueno, "Aging of Blood-Brain Barrier and Neuronal Cells of Eye and Ear in SAM Mice," <u>Neurobiol. Aging</u> 20: 117-123 (1999).
59	M.D. Johnson & B.D. Anderson, "Localization of Purine Metabolizing Enzymes in Bovine Brain Microvessel Endothelial Cells: An Enzymatic Blood-Brain Barrier for Dideoxynucleosides?," <u>Pharm. Res.</u> 13: 1881-1886 (1996).
60	A.D. Mooradian, "Effect of Aging on the Blood-Brain Barrier," <u>Neurobiol. Aging</u> 9: 31-39 (1988).
61	W. Pan et al., "Permeability of the Blood-Brain Barrier to Neurotrophins," <u>Brain Res.</u> 788: 87-94 (1998).
62	W.M. Pardridge, "CNS Drug Design Based on Principles of Blood-Brain Barrier Transport," <u>J. Neurochem.</u> 70: 1781-1792 (1998).
63	J.F. Poduslo et al., "Macromolecular Permeability Across the Blood-Nerve and Blood-Brain Barriers," <u>Proc. Natl. Acad. Sci. USA</u> 91: 5705-5709 (1994).
64	J.F. Poduslo & G.L. Curran, "Permeability at the Blood-Brain Barrier and Blood-Nerve Barriers of the Neurotrophic Factors: NGF, CNTF, NT-3, BDNF," <u>Mol. Brain Res.</u> 36: 280-286 (1996).
65	J.J. Ramirez et al., "AIT-082 Accelerates Septodentate Sprouting After Unilateral Entorhinal Cortex Lesion in Rats," <u>Soc. Neurosci. Abstr.</u> 24: 1942 (1998).
66	G.N. Shah & A.D. Mooradian, "Age-Related Changes in the Blood-Brain Barrier," <u>Exp. Gerontol.</u> 32: 501-519 (1997).
67	I. Skoog et al., "A Population Study on Blood-Brain Barrier Function in 85-Year-Olds: Relation to Alzheimer's Disease and Vascular Dementia," <u>Neurology</u> 50: 966-971 (1998).
68	R. Spector, "Hypoxanthine Transport Through the Blood-Brain Barrier," <u>Neurochem. Res.</u> 12: 791-796 (1987).
69	R. Spector, "Hypoxanthine Transport and Metabolism in the Central Nervous System," <u>J. Neurochem.</u> 50: 969-978 (1988).

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (Modified)	ATTY DOCKET NO. 370143-79	SERIAL NO. 09/907,273
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT  David B. Fick et al.	
(Use additional sheets if necessary) PAGE 4 OF 6	FILING DATE July 17, 2001	GROUP 1624

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

70	D. Triguero et al., "Capillary Depletion Method for Quantitation of Blood-Brain Barrier Transport of Circulating Peptides and Plasma Proteins," <u>J. Neurochem.</u> 54: 1882-1888 (1990).
71	W.A. Banks et al., "Measurement of Efflux Rates from Brain to Blood" in <u>Methods in Molecular Biology, Neuropeptide Protocols</u> (G.B. Irvine & C.H. Williams, eds., Humana Press, Totowa, NJ, 1997), pp. 353-360.
72	M.P. Rathbone et al., "Physiology and Pharmacology of Natural and Synthetic Nonadenine-Based Purines in the Nervous System," <u>Drug Develop. Res.</u> 45: 356-372 (1998).
73	M.P. Rathbone et al., "AIT-082 as a Potential Neuroprotective and Regenerative Agent in Stroke and Central Nervous System Injury, <u>Exp. Opin. Invest. Drugs</u> 8: 1255-1262 (1999).
74	W.A. Banks et al., "Effects of Wheatgerm Agglutinin and Aging on the Regional Brain Uptake of HIV-1 gp120," <u>Life Sci.</u> 65: 81-89 (1999).
75	J.S. Bintner et al., "AIT-082, a Hypoxanthine Derivative, Prevents Much of the Decrease in Cerebellar Neuron ATP Following Glutamate Exposure," <u>Soc. Neurosci.</u> 25: 2131 (1999) (abstract).
76	R. Huang et al., "Enhancement of Neuronal Cell Excitability by AIT-082 in Rat Hippocampal Neurons and Its Effects on Second Messenger Systems," <u>Soc. Neurosci.</u> 24: 1941 (1998) (abstract).
77	O.Chu-LaGraff et al., "Effect of AIT-082 on Brain NGF mRNA Levels and Transport of AIT-082 Across the Blood-Brain Barrier," <u>Soc. Neurosci.</u> 24: 1941 (1998) (abstract).
78	F. Caciagli et al., "The Hypoxanthine Derivative AIT-082 Protects Against Neurotoxicity <i>in Vitro</i> and <i>in Vivo</i> ," <u>Soc. Neurosci.</u> 24: 1941 (1998) (abstract).
79	B.H.J. Juurlink et al., "The Hypoxanthine Analogue AIT-082 Promotes Neurite Formation and Regeneration in Cultured Hippocampal Neurons," <u>Soc. Neurosci.</u> 24: 1941 (1998) (abstract).
80	E.M. Taylor et al., " <sup>14</sup> C-AIT082 Crosses the Blood-Brain Barrier and Is Pumped Out of Brain by a Probenecid- and Verapamil-Sensitive Mechanism," <u>Soc. Neurosci.</u> 25: 1758 (1999) (abstract).
81	F. Caciagli et al., "The Hypoxanthine Analogue AIT-082 Mimics the Activity of Guanosine in Affecting Extracellular Adenosine Breakdown and Glutamate Reuptake in Rat Cultured Astrocytes," <u>Soc. Neurosci.</u> 25: 1195 (1999) (abstract).
82	R. Ciccarelli et al., "Guanosine and Related Drugs Stimulate the Production of Neurotrophic Factors from Rat Cultured Astrocytes by Involving Mitogen-Activated Protein Kinase Pathway," <u>Soc. Neurosci.</u> 25: 1013 (1999) (abstract).
83	P.J. Middlemiss et al., "The Synthetic Purine AIT-082 Enhances Recovery After Acute Spinal Cord Crush Injury in Rats," <u>Soc. Neurosci.</u> 25: 1002 (1999) (abstract).
84	P. Di Iorio et al., "The Hypoxanthine Derivative AIT-082 Is Protective Against NMDA- or Kainic Acid-Induced Rat Hippocampal Neurotoxicity <i>in Vivo</i> ," <u>Soc. Neurosci.</u> 25: 756 (1999) (abstract).
85	A.G. Gittis & J.R. Puzosky, "AIT-082 Improves Memory Performance in a Non-Match-to-Sample Task in Rats," <u>Soc. Neurosci.</u> 25: 62 (1999) (abstract).
86	G. Shaw et al., "Purines, Pyrimidines, and Glyoxalines. Part XIII. Some New Unambiguous Syntheses of 5-Aminoglyoxalines and 5-Aminoglyoxaline-4-carboxamides, and a Synthesis of 5-Amino-1-β-D-ribofuranosylglyoxaline-4-carboxamide," <u>J. Chem. Soc.</u> 1959: 1648- (1959).
87	P.R. Birkett et al., "Synthesis and Intramolecular Cyclisation of 5-Aminoimidazolealkanoates and Their Conversion to Purine Derivatives," <u>Synthesis</u> 1991:157-159 (1991).
88	G.M. Blackburn & M.J. Gait, eds., <u>Nucleic Acids in Chemistry and Biology</u> (2d ed., Oxford University Press, 1996), pp. 148-152.
89	S. Lehmann et al., "Neurite Outgrowth of Neurons of Rat Dorsal Root Ganglia Induced by New Neurotrophic Substances with Guanidine Group," <u>Neurosci. Lett.</u> 152:57-60 (1993).

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


FORM PTO-1449 (Modified)	ATTY DOCKET NO. 370143-79	SERIAL NO. 09/907,273
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT David B. Fick et al.	
(Use additional sheets if necessary) PAGE 5 OF 6	FILING DATE July 17, 2001	GROUP 1624

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

90	M. Barinaga, "Carbon Monoxide: Killer to Brain Messenger in One Step," <u>Science</u> 259:309 (1993).
91	A. Verma et al., "Carbon Monoxide: A Putative Neural Messenger," <u>Science</u> 259:381-384 (1993).
92	M. Zuo et al., "Nitric Oxide and Carbon Monoxide Produce Activity-Dependent Long-Term Synaptic Enhancement in Hippocampus," <u>Science</u> 260: 1946-1950 (1993).
93	A. Seiger et al., "Intracranial Infusion of Purified Nerve Growth Factor to an Alzheimer Patient: The First Attempt of a Possible Future Treatment Strategy," <u>Behavioural Brain Res.</u> 57: 255-261 (1993).
94	A. Nitta et al., "Effects of Oral Administration of a Stimulator for Nerve Growth Factor Synthesis in Basal Forebrain-Lesioned Rats," <u>Eur. J. Pharmacol.</u> 250: 23-30 (1993).
95	M.H. Tuszynski & F.H. Gage, "Neurotrophic Factors and Neuronal Loss," in <u>Alzheimer Disease</u> (R.D. Terry et al., eds., Raven Press, New York, 1994), ch. 25, pp. 405-417.
96	R.D. Hawkins et al., "Nitric Oxide and Carbon Monoxide as Possible Retrograde Messengers in Hippocampal Long-Term Potentiation," <u>J. Neurobiol.</u> 25: 652-665 (1994).
97	S.H. Snyder, "NO and CO: The Body's Unprecedented Signaling Molecules," <u>1995 Yearbook of Science and The Future</u> , <u>Encyclopedia Britannica</u> , pp. 84-101.
98	J.Z. Fields et al., "Cardiac Muscarinic Cholinergic Receptors: Biochemical Identification and Characterization," <u>J. Biol. Chem.</u> 253:3251-3258 (1978).
99	D.H. Maurice & R.J. Haslam, "Molecular Basis of the Synergistic Inhibition of Platelet Function by Nitrovasodilators and Activators of Adenylate Cyclase: Inhibition of Cyclic AMP Breakdown by Cyclic GMP," <u>Mol. Pharmacol.</u> 37: 671-681 (1990).
100	I.D. Laviada et al., "Phosphatidylcholine-Phospholipase C Mediates the Induction of Nerve Growth Factor in Cultured Glial Cells," <u>FEBS Lett.</u> 364: 301-304 (1995).
101	A. Aurell et al., "The S-100 Protein in Cerebrospinal Fluid: A Simple ELISA Method," <u>J. Neurol. Sci.</u> 89: 157-164 (1989).
102	J. Barnett et al., "Human $\beta$ Nerve Growth Factor Obtained from a Baculovirus Expression System Has Potent <i>in Vitro</i> and <i>in Vivo</i> Neurotrophic Activity," <u>Exp. Neurol.</u> 110:11-24 (1990).
103	M.M. Bradford, "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Using the Principle of Protein-Dye Binding," <u>Anal. Biochem.</u> 72: 248-254 (1976).
104	A. Dhainaut et al., "New Purines and Purine Analogs as Modulators of Multi-Drug Resistance," <u>J. Med. Chem.</u> 39:4099-4108 (1996).
105	U. Diederichsen & H.W. Schmidt, " $\beta$ -Homoalanyl-PNA: A Special Case of $\beta$ -Peptides with $\beta$ -Sheet-Like Backbone Conformation; Organization in Higher Ordered Structures," <u>Eur. J. Org. Chem.</u> 1998: 827-835 (1998).
106	M. Iwakawa et al., "Synthetic Routes to Nucleoside Analogs of N-Substituted 1,3-Thiazolidines," <u>Can. J. Chem.</u> 56:326-335 (1978).
107	M.L. Peterson & R. Vince, "Synthesis and Biological Evaluation of 4-Purinylypyrrolidine Nucleosides," <u>J. Med. Chem.</u> 34:2787-2795 (1991).
108	D.A. Nugiel et al., "Facile Preparation of 2,6-Disubstituted Purines Using Solid Phase Chemistry," <u>J. Org. Chem.</u> 62:201-203 (1997).
109	K.G. Estep et al., "Synthesis and Structure-Activity Relationships of 6-Heterocyclic-Substituted Purines as Inactivation Modifiers of Cardiac Sodium Channels," <u>J. Med. Chem.</u> 38:2582-2595 (1995).
110	R.E. Dolle & D. McNair, "9-(Sulfoximinoalkyl) Guanine Nucleosides as Potential Antiherpetic Agents," <u>Tetrahedron Lett.</u> 34:1 (133-136) (1993).

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (Modified)	ATTY DOCKET NO. 370143-79	SERIAL NO. 09/907,273
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT David B. Fick et al.	
(Use additional sheets if necessary) PAGE 6 OF 6	FILING DATE July 17, 2001	GROUP 1624



OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


111	S. Van Calenbergh et al., "Synthesis and Structure-Activity Relationship of Analogs of 2'-Deoxy-2'-(3-Methoxybenzamido)adenosine, a Selective Inhibitor of Trypanosomal Glycosomal Glyceraldehyde-3-Phosphate Dehydrogenase," <u>J. Med. Chem.</u> 38:3838-3849 (1995).
112	D.L. Temple, Jrl, "Substituted 6,7-Dihydroimidazo[1,2-a] Purin-9 (4H)-ones," <u>J. Med. Chem.</u> 23:1188-1198 (1980).
113	Y. Mizuno et al., "Novel Protecting Group for the Synthesis of 7 $\alpha$ -D-Pentofuranosylhypoxanthines," <u>J. Org. Chem.</u> 37:39-42 (1972).
114	P.K. Bridson & T.P. Wierich, "Cycle Homologues of Xanthines. I. Imidazo[4,5-e][1,4]Diazepine-5,8-Diones." <u>J. Heterocyclic Chem.</u> 25:1179-1182 (1988).
115	P. Jimonet et al., "Riluzole Series. Synthesis and in Vivo "Antiglutamate" Activity of 6-Substituted-2-benzothiazolamines and 3-Substituted 2-imino-benzothiazolines," <u>J. Med. Chem.</u> 42:2828-2843 (1999).
116	D. Manetti et al., "Design, Synthesis, and Preliminary Pharmacological Evaluation of 1,4-Diazabicyclo[4.3.0]nonan-9-ones as a New Class of Highly Potent Nootropic Drugs." <u>J. Med. Chem.</u> 43:1969-1974 (2000).
117	D. Manetti et al., "Molecular Simplification of 1,4-Diazabicyclo[4.3.0]nonan-9-ones Given Piperazine Derivatives That Maintain High Nootropic Activity," <u>J. Med. Chem.</u> 43:4499-4507 (2000).
118	Q. Dang et al., "A New Regio-Defined Synthesis of PMEA," <u>Nucleosides &amp; Nucleotides</u> 17:1445-1451 (1998).
119	C.L. Gibson et al., "Specific Inhibitors in Vitamin Biosynthesis. Part 10. Synthesis of 7- and 8-Substituted 7-Deazaguanines," <u>J. Chem. Soc. Perkin Trans. 1</u> 18:3025-3032 (1998).

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Please type a plus sign (+) in this box → ☒Approved for use through 10/31/2002. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/907273
		Filing Date	07/17/2001
		First Named Inventor	Fick et al.
		Group Art Unit	1624
		Examiner Name	D. Rao
Sheet 1 of 1	Attorney Docket Number	370143.79	

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document	Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
		WO	9837079		08/27/1998	Arnaiz et al.		
		WO	9533750		12/14/1995	Chen		
		WO	0105783		01/25/2001	Ohlmeyer et al.		
		WO	9714684		04/24/1997	Webb et al.		
		WO	0114371		03/01/2001	Arnaiz et al.		
		WO	0204448		01/17/2002	Diamond et al.		
		WO	0204450		01/17/2002	Glasky et al.		
		WO	0204451		01/17/2002	Glasky et al.		
		WO	02058736		08/01/2002	Taylor		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO Commissioner for Patents, Washington, DC 20231.